publication date: Dec. 9, 2010
In this issue:
ODAC Meeting: Further Restrictions Likely On ESA Use; Changes Advocated by ODAC May Cut Market By 40-50 Percent.
ODAC Member Critical Of Amgen For Price Incentives.
Amgen, J&J Defend ESA Indications.
ODAC Recommends Approval Of Nplate For Thrombocytopenia.
Funding Opportunities: HHMI Commits $300M To Support Early Career Scientists.
Download (PDF 494KB)
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.